证券代码：000790 证券简称：华神科技 公告编号：2025-021 成都华神科技集团股份有限公司 关于四川证监局行政监管措施决定的整改报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 成都华神科技集团股份有限公司（以下简称"公司"）及相关责任人于近日收 到中国证券监督管理委员会四川监管局（以下简称"四川证监局"）出具的《关于 对成都华神科技集团股份有限公司采取责令改正并对黄明良等相关责任人采取 出具警示函措施的决定》（〔2025〕34号）（以下简称"《决定书》"），要求 公司对《决定书》中指出的问题进行整改。具体内容详见公司于2025年5月21日 在巨潮资讯网披露的《关于收到中国证券监督管理委员会四川监管局行政监管措 施决定书的公告》（公告编号：2025-019）。 收到《决定书》后，公司董事会和管理层高度重视，立即向公司全体董事、 监事、高级管理人员及相关部门人员进行了通报、传达，召开专题会议对《决定 书》中涉及的问题进行了全面梳理和针对性分析研讨。同时根据相关法律法规、 规范性文件及公司各项管理制度的规定和要求，结合公司实际情况，按照《决定 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-023 成都华神科技集团股份有限公司 第十三届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都华神科技集团股份有限公司（以下简称"公司"）第十三届监事会第十 五次会议于2025年6月19日以现场会议的方式在公司会议室召开。本次会议通知 于2025年6月16日发出，应到监事3人，实到监事3人，会议由公司监事会主席苏 蓉蓉女士主持，本次会议的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定。 二、监事会会议审议情况 审议通过《关于审议四川证监局行政监管措施决定的整改报告的议案》 经审核，监事会认为：公司高度重视行政监管措施决定中所指出的问题， 对决定书中提出的问题和要求逐一进行整改和落实，形成的整改报告如实反映 了整改工作内容，整改措施切实可行，符合公司的实际情况，监事会将督促公 司认真、持续地落实各项整改措施。监事会同意该整改报告。 具体内容详见公司在巨潮资讯网同日披露的相关公告。 表决结果：同意 3 票，反对 0 票，弃权 ...

第十三届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第二十二 次会议于2025年6月19日以现场与通讯表决相结合的方式在公司会议室召开。本 次会议通知于2025年6月16日发出，本次会议应出席董事9人，实际出席董事9人。 会议由公司董事长黄明良先生主持，公司监事、高级管理人员列席了会议。本 次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的有关规定。 证券代码：000790 证券简称：华神科技 公告编号：2025-022 成都华神科技集团股份有限公司 二、董事会会议审议情况 审议通过《关于审议四川证监局行政监管措施决定的整改报告的议案》 董 事 会 二〇二五年六月二十一日 表决结果：同意9票，反对0票，弃权0票。 三、备查文件 1、公司第十三届董事会第二十二次会议决议。 特此公告。 成都华神科技集团股份有限公司 公司高度重视行政监管措施决定书中所指出的问题，已积极进行整改并明 确管理要求，董事会同意《关于四川证监局行 ...

Meeting Details - The shareholder meeting was held on May 22, 2025, with both on-site and online voting options available [1][2] - A total of 623,719,364 shares were represented, with 156 shareholders participating, representing 111,431,281 shares, which is 17.8656% of the total voting shares [1] Voting Results - Proposal 1: The 2024 Board of Directors Work Report was approved with 120,970,158 votes in favor, accounting for 97.2919% of the valid votes [2][3] - Proposal 2: The 2024 Supervisory Board Work Report was also approved with the same voting results as Proposal 1 [2][3] - Proposal 3: The 2024 Annual Report and its summary received 120,974,694 votes in favor, representing 97.2955% of the valid votes [3][4] - Proposal 4: The 2024 Financial Settlement Report was approved with 120,968,294 votes in favor, accounting for 97.2904% of the valid votes [4][5] - Proposal 5: The 2024 Profit Distribution Plan was approved with 121,092,433 votes in favor, representing 97.3902% of the valid votes [5][6] - Proposal 6: The reappointment of the accounting firm was approved with 120,929,447 votes in favor, accounting for 97.2591% of the valid votes [6] - Proposal 7: The proposal for the 2025 comprehensive credit and guarantee limit was approved with 121,073,933 votes in favor, representing 97.3754% of the valid votes [6] Legal Opinion - The meeting and voting procedures were confirmed to be legal and valid according to relevant regulations and the company's articles of association [6]

Group 1 - The legal opinion letter confirms the legality of the convening and holding procedures of the 2024 annual general meeting of Chengdu Huasheng Technology Group Co., Ltd. [1][2] - The meeting was convened by the company's 13th Board of Directors and publicly announced on April 29, 2025, detailing the time, location, and agenda [2][3] - The meeting was held on May 22, 2025, combining on-site and online voting methods, with the location being the company's research complex in Chengdu [3][4] Group 2 - A total of 156 shareholders participated in the meeting, representing 124,337,351 shares, which is 19.9348% of the total voting shares [4] - The meeting's attendees included company directors, supervisors, senior management, and the lawyers from the law firm [4] - The voting results for various resolutions were as follows: - The 2024 Board of Directors' work report was approved with 120,970,158 votes in favor, 3,342,377 against, and 24,816 abstentions [6] - The 2024 Supervisory Board's work report received the same voting results as the Board of Directors' report [6] - The 2024 annual report was approved with 120,974,694 votes in favor, 3,342,377 against, and 20,280 abstentions [6] - The 2024 financial settlement report was approved with 120,968,294 votes in favor, 3,342,377 against, and 26,680 abstentions [6] - The profit distribution plan for 2024 was approved with 121,092,433 votes in favor, 3,218,238 against, and 26,680 abstentions [6] - The proposal to reappoint the accounting firm was approved with 120,929,447 votes in favor, 3,342,688 against, and 65,216 abstentions [6] - The proposal for the 2025 comprehensive credit application and guarantee limit was approved with 121,073,933 votes in favor, 3,202,438 against, and 60,980 abstentions [5][6] Group 3 - The legal opinion concludes that the meeting's convening, participant qualifications, and voting procedures were all in compliance with relevant laws, regulations, and the company's articles of association [6]

成都市高新区交子大道 333 号中海国际中心 E 座 602 室 电话：028-65585333 传真：028-66266533 邮编：610041 北京国枫（成都）律师事务所 关于成都华神科技集团股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]D0015 号 致：成都华神科技集团股份有限公司（贵公司） 北京国枫（成都）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务 管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业 务执业规则》"）等相关法律、行政法规、规章、规范性文件及《成都华神科技集团股 份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-020 成都华神科技集团股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席的情况 1、会议召开的时间： （1）现场会议时间 2025年5月22日（星期四）下午14:00。 （2）网络投票时间 2025年5月22日，其中，通过深圳证券交易所交易系统进行网络投票的时间 为：2025年5月22日9:15--9:25，9:30--11:30，13:00--15:00；通过深圳证券交易所 互联网投票系统投票的时间为：2025年5月22日9:15至15:00期间的任意时间。 2、现场会议地点：成都市高新西区蜀新大道 1168 号公司一楼多功能厅 3、会议召开方式：现场表决与网络投票相结合 4、会议召集人：董事会 5、会议主持人：董事长黄明良先生 6、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 7、出席的总体情况： （1）出席现场会议及网络投票股东情况： 公司总股份 623,719,364 股，通过现场和网络投票的 ...

Core Viewpoint - Huasheng Technology (SZ000790) has received an administrative regulatory decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, leading to a requirement for corrective measures and warnings issued to key executives [2][4][5]. Group 1: Accounting Issues - The company has been found to have irregular accounting practices, including misclassification of advertising expenses as intangible assets by its subsidiary Hainan Rongsheng Hong Technology Co., Ltd. in 2021 [2]. - In 2023, another subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., recognized revenue from medical device sales without actual transfer of control to customers, leading to subsequent returns [2]. - Additionally, sales expenses from Chengdu Yuanhong Mineral Water Co., Ltd. were incorrectly accounted for in other subsidiaries, affecting performance assessment accuracy [2]. Group 2: Non-operational Fund Occupation - In 2021, Hainan Huasheng Development Holding Co., Ltd., a subsidiary, prepaid non-main business contract funds, which were later returned after five months, during which some funds flowed into companies controlled by the actual controller, constituting non-operational fund occupation [3]. Group 3: Internal Control Deficiencies - The internal control systems of the subsidiaries are inadequate, with issues such as improper expense reimbursement documentation and non-compliance with procurement management protocols [3]. - The company lacks a robust internal control system for large non-main business expenditures, leading to non-operational fund occupation in 2021 [3]. Group 4: Executive Accountability - Key executives, including Huang Mingliang (Chairman and President), Li Jun (Vice President and CFO), and Song Gang (Vice President), have been held responsible for the identified accounting and internal control issues [4][5]. Group 5: Company Performance - In 2024, Huasheng Technology reported revenue of 864 million yuan, a year-on-year decrease of 13.89%, and a net profit attributable to shareholders of -6.69 million yuan, down 124.19% [8]. - In the first quarter of 2025, the company achieved revenue of 127 million yuan, a decline of 29.21%, with a net profit of -14.59 million yuan, a drop of 740.09% year-on-year [9].

Group 1 - Sanofi's innovative drug company, Sangfor, has granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707, marking a significant milestone for domestic pharmaceutical companies in entering the global market [1] - Pfizer will pay a non-refundable and non-offsettable upfront payment of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales revenue share based on product sales in authorized regions [1] Group 2 - Yipinhong announced the acquisition of a 15.25% stake in its subsidiary Guangzhou Rui'an Bo from minority shareholder Arthrosi for $6.8 million (approximately 49 million RMB) to enhance its market rights for the innovative drug AR882 in China and to promote efficient research and rapid market entry [2] - The transaction's pricing and the ongoing technical support from Arthrosi will be closely monitored for future clinical progress and market access efficiency [2] Group 3 - Huasheng Technology received an administrative regulatory measure from the Sichuan Securities Regulatory Bureau, which ordered the company to rectify issues related to accounting irregularities, non-operating fund occupation, and inadequate internal controls [3] - The regulatory action highlights weaknesses in the company's governance structure and compliance awareness, potentially affecting the rights of minority investors [3] Group 4 - Fosun Pharma announced the resignation of Rong Yang, CEO of its U.S. subsidiary, due to personal reasons, raising concerns about the continuity of leadership and strategic direction in the critical U.S. market for innovative drug commercialization [4] - The company is currently expanding its capabilities in the U.S. for both generic and innovative drug registration and commercialization [4]

Core Viewpoint - Chengdu Huasheng Technology Group Co., Ltd. received an administrative supervision decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, which require corrective actions and warnings for responsible individuals [1][2][3]. Group 1: Administrative Supervision Measures - The company was found to have incorrectly recorded intangible assets and recognized revenue from medical device sales without actual transfer of control to customers, leading to issues with revenue recognition [1][2]. - There were instances of non-operating fund occupation and failure to disclose related party transactions with the actual controller, which violated internal control regulations [2][3]. - The responsible individuals, including the chairman and other executives, received warning letters for their lack of diligence in addressing these issues [3]. Group 2: Required Actions and Compliance - The company is required to conduct a thorough review of its financial accounting, fund usage, and internal control weaknesses, and to implement effective measures for rectification [3][4]. - A written report detailing corrective measures must be submitted to the regulatory authority within 30 days of receiving the decision [3][4]. - The company emphasized its commitment to improving compliance with laws and regulations, enhancing operational standards, and maintaining the interests of shareholders [4][5].